AUS
NZ
UK
CA
USA
IND
Ceretas Limited has submitted an application for admission to the ASX Official List, marking a pivotal step for the Brisbane-based medical technology firm entering public markets. The company is pioneering a portable, non-invasive therapeutic ultrasound platform aimed at treating Alzheimer's disease and other neurodegenerative disorders. The listing application proposes the quotation of approximately 71,375,000 fully paid ordinary shares at the start of trading. This development underscores a major milestone for the emerging Queensland medtech company.
Key Points
- Ceretas Limited (CTS) has lodged an application for ASX Official List admission
- Developing a portable, non-invasive therapeutic ultrasound platform targeting neurodegenerative disease treatment
- Application seeks quotation of an estimated 71,375,000 fully paid ordinary shares at quotation commencement
- Headquartered in Brisbane, Queensland, with registered office at Level 4, 260 Queen Street
- Rachel de las Heras serves as Managing Director and CEO
- John Arthur Keep acts as Non-Executive Chairperson of the board
Ceretas Limited’s Innovation in Portable Ultrasound Therapy for Neurological Disorders
Ceretas Limited is a medical technology company focused on developing therapeutic solutions for neurological diseases. Its core innovation is a portable, non-invasive therapeutic ultrasound platform designed to treat Alzheimer's disease and other neurodegenerative conditions. This technology aligns with the company’s strategic emphasis on non-invasive treatment modalities within the medtech sector, an area of growing clinical and commercial interest.
Incorporated on 21 October 2024 under the Corporations Act 2001 (Cth), Ceretas holds Australian Business Number 15 681 662 224 and ACN 681 662 224. Operating from its principal office at Level 4, 260 Queen Street, Brisbane, Queensland 4000, the company conducts its primary business activities in Australia. Investor enquiries can be directed to 07 3543 4424 or [email protected]. Additional details about its operations and technology are available at https://ceretas.com.au.
Leadership and Board Composition at Ceretas Limited
The company’s board consists of five directors responsible for strategic oversight and governance. John Arthur Keep serves as Non-Executive Chairperson, overseeing board functions and corporate governance. Rachel de las Heras holds the dual role of Managing Director and CEO, spearheading operational and strategic initiatives. Anthony James Keating is Executive Director, contributing operational expertise.
Additionally, Samuel Alan Wetzler and Stuart Crozier serve as Non-Executive Directors, providing independent oversight and specialist guidance. Al Rey Lunar is Chief Financial Officer, managing financial operations, while Nicola Maxine Farley acts as Company Secretary, overseeing corporate compliance and governance. Nicola Maxine Farley is also the ASX compliance contact, reachable at Level 24, St Martins Tower, 44 St Georges Terrace, Perth WA 6000, phone +61 8 6211 5099 or mobile +61 414 687 779.
Details of Securities for ASX Quotation in Listing Application
Ceretas Limited’s ASX listing application requests quotation of fully paid ordinary shares, estimating a maximum of 71,375,000 shares at the commencement of trading. This figure is indicative, with provisions for notifying ASX of any changes before quotation begins. This share structure will form the foundation of Ceretas’ public capital structure upon successful listing.
By submitting its application, Ceretas has agreed to the terms outlined in Appendix 1A of the ASX Listing Rules, warranting that all provided information and documentation are accurate, complete, and not misleading. The company indemnifies ASX to the fullest extent permitted by law against claims arising from any breach of this warranty. The application and supporting documents will be published on the Market Announcements Platform upon admission.
Administrative and Compliance Setup for ASX Listing
Ceretas manages its company secretarial and compliance functions internally through Nicola Maxine Farley, foregoing third-party service providers. The registered and principal administrative offices are co-located in Brisbane, Queensland, facilitating streamlined governance and administration.
Prior to official listing, key details about Ceretas’ listing application have been disclosed on the ASX website at https://www2.asx.com.au/listings/upcoming-floats-and-listings, providing transparency to market participants and investors. All terminology in the application aligns with definitions in the ASX Listing Rules. Ceretas has no prior listings on other exchanges and holds no foreign incorporation references.
Medical Technology Sector and Therapeutic Ultrasound Innovation
Operating in the medical technology sector, Ceretas focuses on developing diagnostic and therapeutic devices, with a niche in therapeutic ultrasound. This non-invasive treatment approach addresses clinical challenges where invasive procedures pose risks or limitations. Alzheimer's and neurodegenerative diseases represent significant global health burdens, driving demand for innovative therapies.
Ceretas’ technology reflects current medtech trends favoring portable, non-invasive solutions that enhance patient acceptance and accessibility. Therapeutic ultrasound applications are under active research for various clinical uses, and Ceretas’ focus on neurodegenerative disease treatment highlights a strategic market and clinical opportunity.
Queensland Medtech Ecosystem and Ceretas’ Operational Base
Ceretas is headquartered in Queensland, embedding itself within Australia’s expanding medical technology ecosystem. Its Brisbane office at Level 4, 260 Queen Street situates the company within a vibrant health and medical science hub, benefiting from local research institutions, clinical networks, and medtech infrastructure.
This central location supports Ceretas’ development and commercial activities as it advances toward ASX listing and public market participation.
ASX Listing Application Process and Regulatory Compliance
The company’s listing application complies with ASX Listing Rules, specifically Appendix 1A governing official list admissions. The application specifies the estimated number and class of securities for quotation, with provisions for pre-quotation notifications of any changes. Ceretas confirms adherence to information and documentation requirements outlined in the ASX Listing Information Form and Checklist.
By submitting the Appendix 1A form, Ceretas commits to ASX Listing Rules compliance and warrants the accuracy and completeness of all application materials. ASX will publish the application documents via the Market Announcements Platform upon admission, formalizing Ceretas’ path to official listing and public quotation.
Corporate Governance and Oversight Framework
Ceretas has established a governance framework consistent with ASX Listing Rules for listed entities. The board’s composition includes a Non-Executive Chairperson, Managing Director/CEO, Executive Director, and two Non-Executive Directors, balancing executive leadership with independent oversight. Directors bring expertise across business management, clinical knowledge, and finance. Corporate compliance and governance administration are managed by the Company Secretary, supported externally as needed.
The governance structure ensures separation of chair and CEO roles, fostering independent board leadership. Non-Executive Directors provide independent judgment and external perspectives on strategic and operational matters. While detailed governance policies such as remuneration and audit committees are not disclosed here, these are expected to be addressed in the company’s prospectus and governance documentation accompanying the listing.
Investor Relations and Contact Information
Investor communications are facilitated through [email protected] and telephone 07 3543 4424. ASX compliance communications are handled by Nicola Maxine Farley at the Perth office address: Level 24, St Martins Tower, 44 St Georges Terrace, Perth WA 6000.
Further company information is available on https://ceretas.com.au. Senior management contacts include Managing Director and CEO Rachel de las Heras at [email protected] and CFO Al Rey Lunar at [email protected]. These channels support engagement with investors, market participants, and stakeholders throughout the listing process and beyond.
